Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.02 | N/A | +22.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.02 | N/A | +22.60% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern about market conditions and emphasized the importance of adapting strategies. They did not provide specific guidance for future performance.
Management highlighted ongoing challenges in the market.
They acknowledged the need for strategic adjustments moving forward.
Organon & Co reported a strong earnings surprise on EPS, but the stock fell significantly by nearly 27%. This sharp decline suggests that investors may be reacting to broader concerns about market conditions and the lack of revenue data. The absence of guidance further adds to uncertainty about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REVVITY INC
Apr 28, 2025